Vistin Pharma ASA (LTS:0RAM) Debt-to-Revenue : 0.04 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAM Vistin Pharma ASA LTS:0RAM
68 GF Score
Price kr19.15
GF Value kr23.27
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Debt-to-Revenue?

Vistin Pharma ASA LTS:0RAM 68 Debt-to-Revenue is 0.04 as of Jun. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 68/100 and a GF Value™ of kr23.27 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

Vistin Pharma ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr15.5 Mil. Vistin Pharma ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr0.0 Mil. Vistin Pharma ASA's annualized Revenue for the quarter that ended in Jun. 2026 was kr400.8 Mil. Vistin Pharma ASA's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 was 0.04.

Vistin Pharma ASA Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Debt-to-Revenue Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.17 0.01 0.00 0.00

Vistin Pharma ASA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.05 0.00 0.00 0.04

LTS:0RAM vs ZTS, UTHR, VTRS: Debt-to-Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vistin Pharma ASA Debt-to-Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vistin Pharma ASA's Debt-to-Revenue falls into.


LTS:0RAM
68GF Score
Vistin Pharma ASA LTS:0RAM
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Vistin Pharma ASA's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0.619) / 452.291
=0.00

Vistin Pharma ASA's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(15.524 + 0) / 400.812
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2026) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 0.04 mean?
Vistin Pharma ASA (LTS:0RAM) has a Debt-to-Revenue of 0.04 as of Jun. 2026.
Is Vistin Pharma ASA's Debt-to-Revenue too high?
Vistin Pharma ASA's current Debt-to-Revenue is 0.04. Overall, Vistin Pharma ASA has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Debt-to-Revenue compare to ZTS and UTHR?
Vistin Pharma ASA's Debt-to-Revenue of 0.04 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Drug Manufacturers company?
A good Debt-to-Revenue depends on the Drug Manufacturers industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Vistin Pharma ASA's current Debt-to-Revenue is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr23.27, compared to a current price of kr19.15 — trading 17.7% below its estimated fair value. The current Debt-to-Revenue is 0.04. Vistin Pharma ASA's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Debt-to-Revenue is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr19.15 is trading 17.7% below its estimated GF Value™ of kr23.27. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Debt-to-Revenue: 0.04
  • GF Value™: kr23.27 vs. price of kr19.15 (17.7% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
68GF Score

Get the complete analysis for LTS:0RAM

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr19.15
Price
kr23.27
GF Value